Business
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transactionToronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental...
About this update from Pharmather Holdings Ltd
[{"type":"text","content":"Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transaction","length":204,"tagName":"p"},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental Illness," signed on April 18, 2026, may help create a more supportive political and regulatory backdrop for innovative ketamine-based programs, particularly where severe unmet need, depression, suicidality, and other difficult-to-treat mental health conditions are involved.","length":597,"tagName":"p"},{"type":"text","content":""We believe the recent U.S. executive order is another signal that policymakers are placing greater urgency on advancing new treatment options for serious mental illness," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "We believe this evolving regulatory environment strengthens the strategic value of our ketamine portfolio, including our microneedle patch program, KetaVault™ partnership portal, retained specialty ketamine programs, and our ongoing economic exposure from the prior sale of our FDA-approved ketamine ANDA."","length":560,"tagName":"p"},{"type":"text","content":"Supportive U.S. Policy Momentum for Serious Mental Illness","length":58,"tagName":"p"},{"type":"text","content":"The executive order is focused on psychedelic drugs for serious mental illness and emphasizes accelerated research, clinical trial participation, data sharing, and real-world evidence generation, including collaboration among HHS, FDA, the Department of Veterans Affairs, and the private sector. PharmaTher believes the broader direction of U.S. policy reflects growing support for accelerating the development of important therapies for patients with severe and treatment-resistant mental health conditions. These measures could contribute to a more supportive backdrop for advancing differentiated ketamine programs, particularly in areas involving severe unmet need, mental health, and veteran-focused treatment opportunities...